Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539520 | 1.00 | LOXL2 (0.60) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL3272996 | 0.89 | LOXL2 (0.56) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL7169246 | 0.87 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL31059889 | 0.87 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL30728863 | 0.85 | LOXL2 (0.53) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL28335219 | 0.85 | LOXL2 (0.67) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL2385292 | 0.83 | LOXL2 (0.64) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL6860219 | 0.83 | LOXL2 (0.64) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL29403791 | 0.83 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAHR | |
| SCHEMBL401081 | 0.83 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116472274-A | Azetidine tryptamine and method of treating psychotic disorders | 吉尔伽美什制药公司 | 2023-07-21 | — | — | CN | disclosed |
| US-9988377-B2 | Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-05 | — | — | US | disclosed |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2013028999-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-28 | — | — | WO | disclosed |
| US-7767691-B2 | Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system | GLAXO GROUP LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| WO-2010059711-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20080194618-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| EP-1937068-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007022351-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-22 | — | — | WO | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-0061333-B1 | 9-(2-(3-INDOLYL)ETHYL)-1-OXA-4,9-DIAZASPIRO(5.5)UNDECAN-3-ONES | SYNTEX (U.S.A.) INC. (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0061333-A1 | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones | SYNTEX (U.S.A.) INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4332804-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIA, MIGRAINE, VASOSPASTIC DISORDERS AND ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194618-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | LOXL2 1428/4885HRH3 108/4885MTNR1A 67/4885 |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | LOXL2 4230/4885HRH3 1302/4885MTNR1A 180/4885 |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | LOXL2 1184/4885HRH3 23/4885MTNR1A 99/4885 |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | GFRA1, GFRA2, GFRA3 | LOXL2 3949/4885HRH3 127/4885MTNR1A 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.